#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Medulloblastoma recurrent Hypersensitivity pneumonitis Arterial disorder Chondrodystrophy Immune-mediated enterocolitis Pouchitis Spinal cord injury Mycobacterium abscessus infection Frontotemporal dementia Thermal burn Acute myeloid leukaemia recurrent Neovascular age-related macular degeneration Adenoid cystic carcinoma Craniopharyngioma Friedreich's ataxia More trials…

    Learn about Rare Diseases

    Soft tissue sarcoma – Life with Disease Mitochondrial myopathy – Life with Disease Osteosarcoma recurrent Encephalitis autoimmune Urea cycle disorder Behcet’s syndrome – Treatment Gaucher’s disease type III – Trials in Disease Wiskott-Aldrich syndrome – Life with Disease Pleural mesothelioma malignant – Diagnostics Anaplastic thyroid cancer – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sym023 Acoramidis Hydrochloride Midazolam ASP2957 SGN-ALPV Fludarabine Phosphate Ph. Eur. Sotalol Hydrochloride Fluvastatin Xenon (129Xe) Xxb750 ROPINIROLE FIBRIN Paliperidone Povorcitinib Gskvx000000008885 N-Tec Lasmiditan Obicetrapib Agomelatine Ferumoxytol More therapies…

    Learn about Your Condition

    Hernia repair Von Hippel-Lindau disease Urticaria cholinergic Anogenital warts Primary amyloidosis Pancreatitis chronic Colon cancer stage III Bartonellosis Respiratory tract infection Rhabdomyosarcoma recurrent Lennox-Gastaut syndrome Retinoblastoma Hepato-lenticular degeneration Cardiac failure acute Lysosomal storage disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Paroxysmal nocturnal haemoglobinuria

  • Study on the Safety and Effects of Iptacopan in Children with Paroxysmal Nocturnal Hemoglobinuria (PNH) Aged 2 to 17 Years

    Recruiting

    3 1 1
    Investigated Drugs:
    • Iptacopan Hydrochloride
    France Germany Italy The Netherlands Spain

  • Study on Optimizing Ravulizumab Dosing for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Ravulizumab
    The Netherlands

  • Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Danicopan
    France Germany

  • Study of pegcetacoplan safety and effectiveness in adolescents aged 12-17 with paroxysmal nocturnal hemoglobinuria

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Pegcetacoplan
    The Netherlands Spain

  • Study of Pozelimab and Cemdisiran in Adults with Paroxysmal Nocturnal Hemoglobinuria Not Responding Well to Current C5 Inhibitor Treatment

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Cemdisiran
    • Pozelimab
    Italy Poland Spain

  • Study on the Safety and Effectiveness of Crovalimab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

    Not recruiting

    2 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Crovalimab
    France Germany Hungary Italy
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!